Intellia Therapeutics Corporate Overview 2023 | Genome Editing

Intellia Therapeutics is a genome editing company developing CRISPR/Cas9-based treatments for genetic diseases including ATTR amyloidosis, hereditary angioedema, and alpha-1 antitrypsin deficiency. The presentation outlines Intellia's clinical pipeline, platform technologies, and strategic collaborations with partners including Regeneron and Novartis.